About Kerberos Proximal Solutions
Kerberos Proximal Solutions Inc., in Cupertino, Calif., developed proximal embolic-protection technology to recover debris dislodged during angioplasty and stent placement. The Kerberos device could lower significantly the embolic risk of these measures and make them more accessible to a broader patient population. The RCT BioVentures investment helped Kerberos perfect a mechanical model and demonstrate its use in animals. Kerberos received clearance from the U.S. Food and Drug Administration in September 2004 for coronary and peripheral use of the Rinspiration System. Rinspiration is focal simultaneous rinsing and aspiration administered by a single catheter. Later in the same month, Kerberos performed its 200th case of Rinspiration at New York Presbyterian/Columbia University Medical Center. The continued success of the Kerberos system in multi-device treatment interventions was one of the showcases highlighted at the IX Live Symposium of Complex Coronary and Cardiovascular Cases in New York in June 2006. In August 2006, FoxHollow Technologies ((Nasdaq: FOXH) announced a merger agreement to acquire Kerberos. Under the agreement, FoxHollow committed to pay about $32 million at closing, of which about $13 million it paid in stock.
Latest Kerberos Proximal Solutions News
May 8, 2012
MFS Investment Management, which invented the mutual fund, adds 7 million shares to its stake in St. Jude Medical, taking its share to 10% of the medical device maker; also, Smith &amp; Nephew's Bioventus ortho-biologics JV fledges, Kalypto deal closes; Kerberos Proximal Solutions puts Rinspiration on the auction block; NeuroLogica helps develop 1st mobile stroke ambulance; Xtend Medical gets into the entertainment game; plus, a Funding Roundup and analysts' ups and downs. St. Jude Medical's&nbsp;(NYSE:STJ) largest investor boosted its stake by more than 30%, to some 27.2 million shares, or about 10% of the medical device maker. News Well, Orthopedics, Wall Street Beatread more
Kerberos Proximal Solutions Frequently Asked Questions (FAQ)
When was Kerberos Proximal Solutions founded?
Kerberos Proximal Solutions was founded in 2001.
Where is Kerberos Proximal Solutions's headquarters?
Kerberos Proximal Solutions's headquarters is located at 10600 North Tantau Avenue, Cupertino.
What is Kerberos Proximal Solutions's latest funding round?
Kerberos Proximal Solutions's latest funding round is Acquired.
Who are the investors of Kerberos Proximal Solutions?
Investors of Kerberos Proximal Solutions include Foxhollow Technologies, Three Arch Partners and Alta Partners.
Who are Kerberos Proximal Solutions's competitors?
Competitors of Kerberos Proximal Solutions include Endologix, Tryton Medical, Small Bone Innovations, Sonitus Medical, IDev Technologies and 7 more.
Compare Kerberos Proximal Solutions to Competitors
Endologix is a company focused on the development and manufacturing of minimally invasive treatments for aortic disorders, operating within the medical devices industry. The company's main offerings include a variety of endovascular stent grafts, which are used for the treatment of abdominal aortic aneurysms (AAA), a condition characterized by a weakening of the wall of the aorta that can lead to a balloon-like enlargement. Endologix primarily serves the healthcare sector, particularly in areas related to vascular disease and aortic disorders. It was founded in 1992 and is based in Irvine, California.
Micell Technologies aims to bring together the clinical advantages of a drug-eluting stent with the long-term safety and stability of a bare metal stent.
SquareOne is developing a stent delivery system.
TriReme Medical is a privately held medical device company dedicated to the development, manufacturing, and commercialization of next generation percutaneous devices for the treatment of complex coronary and peripheral arterial disease. The company is focused on the US and the emerging Asian markets.
InterRad Medical specializes in innovative catheter securement solutions within the healthcare sector. The company's flagship product, the SecurAcath, is a device that secures catheters subcutaneously without the need for adhesives or sutures, designed to reduce complications and improve patient care. InterRad Medical's products are primarily utilized in the healthcare industry, with a focus on improving outcomes for patients requiring catheterization. It was founded in 2000 and is based in Plymouth, Minnesota.
CleveX focuses on the development of medical devices for skin biopsy, closure, and repair in the healthcare sector. The company provides innovative solutions designed for use by professionals in primary care, family practices, OB/GYN, and dermatology. These products are aimed at improving patient outcomes in tissue management and surgical procedures. It was founded in 2003 and is based in Columbus, Ohio.